Summary of Nuvation Bio Conference Call Company Overview - **Company**: Nuvation Bio (NYSE:NUVB) - **Event**: 2026 Conference on March 11, 2026 Key Points on Ibtrozi Launch - **Launch Performance**: The Ibtrozi launch has been successful, treating 432 patients in the first two quarters, averaging over 200 patients per quarter, which is six times the initial performance of Augtyro [4][39] - **Sales Dynamics**: Sales have been successful across all territories with 47 sales representatives achieving success in various geographies [5] - **Lines of Therapy**: Majority of prescriptions are in later lines of therapy, typical for oncology launches, but there is a growing trend in first-line use [4][14] Patient Treatment Insights - **Duration of Therapy**: Progression-free survival in the first-line setting is approximately 46 months, decreasing significantly in later lines [9][11] - **Reimbursement Challenges**: Few reimbursement challenges have been reported, with only a small number of patients seeking assistance through the Nuvation Connect portal [12][14] - **Discontinuation Rates**: 75% of discontinuations are from third-line plus patients, indicating that earlier line patients are remaining on the drug longer [29] Financial Projections - **Sales Estimates**: The company is comfortable with a consensus estimate of just under $150 million for the first full year of sales, expecting growth to be non-linear [31][32] - **Gross to Net Dynamics**: The gross to net ratio was above 25% in the first quarter, with expectations for gradual improvement [38] Market Expansion Potential - **ROS1 Testing**: The market for ROS1 testing is expected to grow as RNA testing becomes standard, which is 30% more sensitive than DNA testing [41][42] - **NCCN Guidelines Impact**: Changes in NCCN guidelines are expected to increase ROS1 TKI use, as IO is now contraindicated [43][44] Competitive Landscape - **Comparison with Competitors**: Ibtrozi shows superior efficacy compared to Nuvalent's drug, with higher response rates and intracranial response rates [66][69] - **Adjuvant Plans**: Nuvation Bio is the only ROS1 TKI pursuing adjuvant studies, which could lead to significant market share [79][85] Safusidenib Development - **IDH1 Inhibitor**: Safusidenib shows promising results in low-risk, low-grade glioma, with a response rate of 44% compared to Vorasidenib's 11% [90] - **Future Studies**: Ongoing studies aim to expand approval across multiple glioma segments, with potential for approval based on response rates [91][96] Conclusion - Nuvation Bio is positioned strongly in the oncology market with Ibtrozi and Safusidenib, showing promising launch metrics, competitive advantages, and a clear path for future growth and market expansion.

Company Overview - Nuvation Bio is a commercial stage biotechnology company with several products in late-stage development [2] - The company’s lead commercial asset, IBTROZI (taletrectinib), is a next-generation ROS1 inhibitor approved for treating ROS1-positive non-small cell lung cancer [2] Product Pipeline - Safusidenib is a potentially best-in-class mutant IDH1 inhibitor currently in a pivotal study for treating both high-grade and low-grade gliomas [3] - NUV-868 is a BD2-selective BET inhibitor that has completed Phase I studies [3] - The company is also developing a novel drug-drug conjugate preclinical program aimed at providing targeted therapy to cancers [3] Financial Position - Nuvation Bio has a cash balance of approximately $589 million following a recent deal with Eisai [4] - The company anticipates a path to profitability without the need for further funding [4] - IBTROZI is being commercialized in partnership with Eisai, Innovent, and Nippon Kayaku [4]

Summary of Nuvation Bio Conference Call Company Overview - Nuvation Bio is a commercial stage biotechnology company with several late-stage products, including Iptrozi (talotrectinib), a ROS1 inhibitor for non-small cell lung cancer, and Safusidenib, a mutant IDH1 inhibitor for gliomas [2][20] Key Products and Developments Iptrozi (Talotrectinib) - Approved in June for treating ROS1 positive non-small cell lung cancer - Achieved 432 new patient starts since launch, reflecting a 6X faster launch than competitors [5] - Sales increased from 204 new patient starts in Q3 to 216 in Q4, a 6% quarter-over-quarter increase [4] - Market leader in ROS1 TKIs with 90% of lives covered to label [5] - Response rate of 89% and median duration of response (DOR) of 50 months, which is elite among oncology agents [8][9] - Theoretical market opportunity in the U.S. could approach $5 billion with RNA testing becoming the standard [18] Safusidenib - A mutant IDH1 inhibitor for gliomas, with significant commercial potential due to long survival rates in patients [21] - Currently in pivotal studies, showing promising response rates compared to the only approved drug, vorasidenib [26] - Anticipated to enroll 300 patients in pivotal studies, with readouts expected by 2029 [27] BD2-Selective BET Inhibitor - Most selective BET inhibitor in development, having completed phase 1 studies [31] Drug-Drug Conjugate (DDC) Platform - Innovative approach using two small molecules for targeted cancer therapy, currently in optimization phase [32] Financial Overview - Current cash balance of approximately $589 million, expected to increase to $620 million with upcoming milestones [3][33] - Revenue stacking potential from Iptrozi could lead to significant long-term revenue growth [17] Market Dynamics - Shift in NCCN guidelines contraindicating immuno-oncology (IO) for ROS1 lung cancer, favoring ROS1 agents like Iptrozi [19] - Increased incidence of ROS1 fusions detected through RNA testing, potentially expanding the patient pool and market opportunity [18] Clinical Data and Efficacy - Iptrozi shows superior efficacy compared to first-generation TKIs, with a lower discontinuation rate of 6.5% [11][12] - Safusidenib demonstrates lower progression rates and higher response rates compared to vorasidenib [25][26] Strategic Priorities - Focus on continuing the successful launch of Iptrozi and increasing awareness of next-generation sequencing (NGS) testing in the community [36][37] - Rapid enrollment in pivotal studies for Safusidenib, targeting high-grade and high-risk low-grade gliomas [39] Conclusion - Nuvation Bio is positioned for significant growth with its innovative therapies and strong market presence, particularly in the ROS1 positive lung cancer and glioma spaces, supported by robust clinical data and strategic financial management [34][35]